OptiBiotix Health PLC Distribution agreement for CholBiome®x3 (1183W)
09 Diciembre 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1183W
OptiBiotix Health PLC
09 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Distribution agreement for CholBiome(R)(x3) in the
Philippines
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd. ("ProBiotix"), has signed an exclusive agreement with
CTC Far East Philippines, Inc. ("CTC"), a subsidiary of the CTC
Group, for the distribution of ProBiotix's proprietary formulation
CholBiome(R)x3 in the Philippines.
Under the terms of the agreement, ProBiotix will supply
CholBiome(R)(x3) , featuring its cholesterol and blood
pressure-reducing probiotic strain Lactobacillus plantarum LP(LDL)
(R), to CTC for its distribution in the Philippines. Exclusivity is
subject to minimum order quantities and a multiyear business plan
in an attempt to improve security of income and revenue growth.
"CTC Group (CTC), is the global business network group of the
Koen Visser Corporation. CTC is active in Europe, Africa, South and
Central America, Caribbean and Asia with head office located in
Amsterdam, The Netherlands. CTC Group is a global life science
partner-provider of innovative product solutions for food,
beverage, personal care products, and health and wellness."
The Philippines is a country with an expanding population of
over 100 million and an emerging economy with annual GDP growth
rates above 6% sustained over the last 5 years (World Bank).
Cardiovascular disease is the leading cause of death in the
country, with high blood pressure affecting almost 20% of its
population (WHO).
Steve Prescott, CEO of ProBiotix, commented: "We are pleased to
announce this agreement with CTC, which will expand ProBiotix's
presence in the emerging Asia-Pacific region. CTC was chosen as our
partner for CholBiome(R)(x3) product introduction in the
Philippines because of their extensive knowledge of the local
market and consistent track record successfully launching new
products."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Goetz Partner Securities Limited
Brigitte de Lima T +44 (0)203 897 6663 |
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRUGGMWPUPBGBQ
(END) Dow Jones Newswires
December 09, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024